tag:blogger.com,1999:blog-2486797219477952862.post1662733779256415168..comments2013-04-03T07:48:29.453-07:00Comments on Arizona Bioscientist: Medivation Initiates Second Pivotal Phase 3 Trial Of Dimebon™ In Patients With Alzheimer's DiseaseMatt Nelsonhttp://www.blogger.com/profile/09958736642345934009noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-2486797219477952862.post-51679221296137050552008-06-26T06:40:00.000-07:002008-06-26T06:40:00.000-07:00As a point of clarification, the phrasing "Medivat...As a point of clarification, the phrasing "Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon" is not really correct. The first (Russian) Dimebon study was <I>not</I> a Phase 3 trial. It was "Phase 2." Upon retrospective review, the FDA determined that it met the critera for a pivotal trial for the Alzheimer's indication. Results of that study are to be published in <I>The Lancet</I> in June or July 2008.AMachttps://www.blogger.com/profile/08872008617279528583noreply@blogger.com